Physician profile
William B Townsend
NPI 1619959061
$2,631.01
in general payments reported to CMS, 2019-2025
32 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $338 · 2021: $464 · 2022: $393 · 2023: $401 · 2024: $181 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951 · Education: $31.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.87 |
| Education | $31.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $342.02 | 2019-2024 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $300.37 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Kowa Pharmaceuticals America, INC. | $297.25 | 2020-2023 | Livalo, Seglentis |
| Pfizer INC. | $285.69 | 2019-2025 | |
| Lilly USA, LLC | $191.38 | 2019-2023 | Emgality, Jardiance |
| Novo Nordisk INC | $133.37 | 2019-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $119.12 | 2019-2022 | |
| Amgen INC. | $106.96 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $92.82 | 2021-2024 | |
| Glaxosmithkline, LLC. | $91.30 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $87.37 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.07 | 2019-2024 | Eliquis |
| Horizon Therapeutics Plc | $62.48 | 2020-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $52.78 | 2020-2021 | |
| Amarin Pharma, INC. | $51.34 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $45.62 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.50 | 2019-2021 | |
| Medicure Pharma INC. | $29.22 | 2021 | |
| Astellas Pharma US INC | $25.61 | 2019-2022 | |
| Corium, LLC | $19.58 | 2022 | |
| Eisai INC. | $17.51 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.94 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $16.13 | 2023 | |
| Dexcom, INC. | $15.67 | 2021 | |
| Exact Sciences Corporation | $15.67 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.57 | 2023 | Dificid |
| Biohaven Pharmaceutical Holding Company LTD. | $15.45 | 2022 | |
| Allergan, INC. | $14.90 | 2020 | |
| Esperion Therapeutics, INC. | $14.56 | 2020 | |
| Antares Pharma, INC. | $14.47 | 2019 | |
| Circassia INC. | $13.34 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.